Media Articles Related to Tykerb (Lapatinib)
SHAVE a Big Plus in Breast Cancer
Source: Medscape Hematology-Oncology Headlines [2015.05.22]
Dr Kathy Miller makes her top picks of breast cancer studies to watch at ASCO, noting trials in ER-positive and HER2-positive disease--and a small surgical study that may yield big benefits.
Family history has 'no adverse effect' on breast cancer outcomes
Source: Anxiety / Stress News From Medical News Today [2015.05.20]
Women diagnosed and treated for breast cancer under the age of 41 have an outlook just as good with family history of the disease as without - with similar prognosis of recurrence.
A blood test for early detection of breast cancer metastasis
Source: Breast Cancer News From Medical News Today [2015.05.18]
Research findings from Lund University in Sweden now provide new hope for a way of detecting metastases significantly earlier than is currently possible.
siRNA-toting nanoparticles inhibit breast cancer metastasis
Source: Breast Cancer News From Medical News Today [2015.05.15]
Researchers at Case Western Reserve University combined finely crafted nanoparticles with one of nature's potent disrupters to prevent the spread of triple-negative breast cancer in mouse models.
Women with inherited KRAS-variant mutation may be at increased breast cancer risk due to acute estrogen withdrawal
Source: Breast Cancer News From Medical News Today [2015.05.14]
UCLA researchers have discovered that for women with a relatively common inherited mutation, known as the KRAS-variant, abrupt lowering of estrogen may increase their breast cancer risk and impact...
Published Studies Related to Tykerb (Lapatinib)
Double-blind, placebo-controlled, multicenter, randomized, phase IIb neoadjuvant
study of letrozole-lapatinib in postmenopausal hormone receptor-positive, human
epidermal growth factor receptor 2-negative, operable breast cancer. 
factor receptor 2 (HER2) -negative operable breast cancer... CONCLUSION: The combination of letrozole-lapatinib in early breast cancer was
Randomized trial of lapatinib versus placebo added to paclitaxel in the treatment
of human epidermal growth factor receptor 2-overexpressing metastatic breast
in patients with HER2-overexpressing metastatic breast cancer (MBC)... CONCLUSION: This trial demonstrated that lapatinib combined with paclitaxel
Target-specific, histology-independent, randomized discontinuation study of
lapatinib in patients with HER2-amplified solid tumors. 
focused on the drug target rather than on histology... CONCLUSIONS: Basing trial eligibility on the presence of a genetic target, versus
Effects of lapatinib monotherapy: results of a randomised phase II study in therapy-naive patients with locally advanced squamous cell carcinoma of the head and neck. [2011.08.23]
BACKGROUND: Lapatinib is a dual inhibitor of epidermal growth factor receptor (EGFR) and human EGFR-2 (HER-2) tyrosine kinases. This study investigated the pharmacodynamic and clinical effects of lapatinib in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN)... CONCLUSION: Short-term lapatinib monotherapy did not demonstrate apoptotic changes, but provided evidence of clinical activity in locally advanced SCCHN, and warrants further investigation in this disease.
Lapatinib activity in premalignant lesions and HER-2-positive cancer of the breast in a randomized, placebo-controlled presurgical trial. [2011.08]
Dual epidermal growth factor receptor (EGFR) and HER2 targeting with the tyrosine kinase inhibitor lapatinib is approved for treating advanced HER2-positive breast cancer and can prevent estrogen receptor (ER)-negative mammary tumors in HER2 transgenic mouse models... In conclusion, short-term lapatinib decreased cell proliferation in DIN, DH, and invasive HER-2-positive (especially ER-negative) breast cancer, thus providing the rationale for further clinical development of lapatinib for breast cancer prevention in high-risk patients, including those with HER-2-positive DIN.
Clinical Trials Related to Tykerb (Lapatinib)
Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Inflammatory Breast Cancer [Recruiting]
The double blind part of the study is being conducted to compare the efficacy and safety of
pazopanib in combination with lapatinib with that of lapatinib alone in subjects with
inflammatory breast cancer whose tumors overexpress the ErbB2 protein. There is also an
Open-label pazopanib arm to this study designed to test whether pazopanib given alone and
lapatinib given alone would be safe and effective to treat patients with inflammatory breast
Preoperative Chemotherapy With Paclitaxel, Gemcitabine, and Lapatinib (Tykerb´┐Ż) (PGT) [Recruiting]
Primary objectives :
1. To evaluate the recommended dose of the combination of paclitaxel, gemcitabine, and
lapatinib (Tykerb«) (PGT) as preoperative chemotherapy in patients with HER2 positive
operable breast cancer
Secondary objectives :
1. To evaluate the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of PGT
2. To determine the safety profile
3. To assess pCR in primary tumor and axillary LN
4. To evaluate clinical response rate, disease free survival (DFS), and overall survival
5. To assess breast conserving rate after preoperative PGT
Lapatinib and Cetuximab in Patients With Solid Tumors [Recruiting]
This trial is for patients with colon cancer, head and neck cancer and lung cancer that has
not responded to standard therapy.
Cetuximab targets a receptor on cancer cells called the Epidermal Growth Factor Receptor or
EGFR. It is thought that this receptor is turned "on" in some cancers, enabling cancer cells
to divide and grow. Blocking this receptor can turn this signal off. Cetuximab blocks this
receptor from the outside of cancer cells. It is thought that cancer cells can turn this
signal back on by the EGFR joining with a related receptor called ErbB2. Lapatinib blocks
both EGFR and ErbB2 from the inside of cancer cells. In laboratory experiments it has been
found that combining drugs that target both EGFR and ErbB2 might work better in turning this
signal back off. The purpose of this study is to determine the maximum dosages that patients
can tolerate when these two medicines are given at the same time.
In addition, in order to be on this trial, patients must agree to have a tumor biopsy before
starting treatment on this study and 21 days after starting treatment. These biopsies are a
required part of the study. Patients must also agree to have blood drawn for research
testing to see whether genetic differences between patients explain different reactions to
and side effects from, these medicines.
Lapatinib in Metastatic Breast Cancer Resistant to Hormone Therapy [Recruiting]
Two thirds or more of breast cancers are dependent on estrogen for growth. We use a number
of estrogen-blocking medicines for treatment of metastatic breast cancer. The treatment
response to these agents is unpredictable, however, and approximately one-third of patients
with metastatic breast cancer with receptors for estrogen or progesterone have no benefit
from hormonal therapy. Nearly all patients with metastatic breast cancer will eventually
become resistant to hormonal therapy despite the fact that the hormone receptors are still
Some cells make a different class of growth factor receptor called the Epidermal Growth
Factor Receptor. There is a growing body of experimental evidence showing that breast
cancer cells that make Epidermal Growth Factor Receptors are more resistant to hormonal
therapy and have a poorer prognosis. Several investigators have found that the Epidermal
Growth Factor Receptor can activate the estrogen receptor, even in the presence of
estrogen-blocking drugs. Growth of these cells can be slowed by blockade of both Epidermal
Growth Factor Receptor signaling and estrogen-receptor signaling. Lapatinib is a small
molecule which can inhibit two different forms of the Epidermal Growth Factor Receptor. It
has been studied in people with a number of different cancers, including breast cancer, and
a safe dose and its common side effects have been defined.
Our hypothesis is that the Epidermal Growth Factor Receptor is the dominant receptor pathway
used by breast cancers in our patients with hormone-resistant tumors. Drugs like lapatinib
which block several forms of the Epidermal Growth Factor Receptor would best be able to
reverse resistance to hormonal agents.
Study to Assess dHER2+AS15 Cancer Vaccine Given in Combination With Lapatinib to Patients With Metastatic Breast Cancer [Recruiting]
This is a phase I/II study to determine the safety and gain insight into the immune response
of the immunologic agent dHER2+AS15 ASCI when administered in combination with lapatinib.
This study is for patients with metastatic breast cancer (invasive breast cancer with stage
IV disease) that overexpresses HER2 and is resistant to trastuzumab (Herceptin).
The dHER2 + AS15 candidate Antigen-Specific Cancer Immunotherapeutic (ASCI) contains a
recombinant protein termed dHER2, which is a truncated version of the HER2 protein. HER2 is
a protein that is commonly overexpressed in breast cancer. This protein is combined with the
immunological adjuvant AS15 Adjuvant System from GSK (GlaxoSmithKline), which is a liposomal
formulation containing three immunostimulatory components.
Lapatinib is FDA approved for use in combination with capecitabine for the treatment of
subjects with advanced or metastatic breast cancer whose tumors overexpress HER2.
Reports of Suspected Tykerb (Lapatinib) Side Effects
Palmar-Plantar Erythrodysaesthesia Syndrome (84),
Decreased Appetite (46),
Disease Progression (44), more >>